Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alimera Sciences Inc's ILUVIEN Receives Marketing Authorization In Spain For Treatment Of Chronic Diabetic Macular Edema


Thursday, 17 Jan 2013 07:30am EST 

Alimera Sciences Inc announced that the Spanish Agency of Drugs and Medical Devices (Agencia Espanola de Medicamentos y Productos Sanitarios) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. 

Company Quote

4.98
-0.21 -4.05%
19 Sep 2014